Research Progress on Anti-Tumor Mechanism of Tannins in Traditional Chinese Medicine

Hui Ding, Yuxin Wang, Gen Li, Yingling Dong, Xinyu Dai, Chenglong Kang, Kai Li, Haixing Han, Xuling Peng, Xi ChenJournal of Biomedical Research & Environmental Sciences 2023 · DOI

TL;DR

This review synthesizes a decade of research to map out the complex molecular landscape of tannins—polyphenolic compounds found in Traditional Chinese Medicine (TCM)—and their anti-tumor properties. The paper identifies five primary mechanisms—cell cycle arrest, migration inhibition, apoptosis induction, immune enhancement, and antioxidant activity—positioning tannins as promising candidates for targeted, low-toxicity cancer therapies.

What Problem Does This Paper Address?

Despite advances in oncology, many conventional chemotherapies suffer from a lack of "targeting," leading to severe side effects as healthy cells are caught in the crossfire. Researchers are increasingly looking toward natural products, particularly those used in TCM, for compounds that exhibit high efficacy with low systemic toxicity.

Tannins are ubiquitous in the human diet and medicinal plants, yet their chemical complexity and diverse structures have made it difficult to establish a unified understanding of their pharmacological "mode of action." This paper addresses this gap by classifying the latest research into a coherent mechanistic framework, helping researchers navigate the "chemical composition banks" of TCM.

Methods

As a systematic review, the authors analyzed literature from the last decade focusing on the efficacy of various tannin classes (hydrolyzable vs. condensed). They categorized these findings based on established oncological pathways. The paper specifically highlights the structure-activity relationships of key compounds like Ellagic Acid (EA), Gallotannin (GT), and Corilagin, mapping their interactions with specific proteins (e.g., cyclins, CDKs, and Bcl-2 family proteins) and signaling pathways (e.g., NF-κB and VEGF).

Datasets

Not applicable. This is a literature review and does not introduce new experimental datasets or benchmarks. It draws upon previously published in vitro and in vivo studies.

Key Insights and Ideas

  • The S-Phase Blockade: One of the most significant "aha moments" is the specificity of tannins like Ellagic Acid (EA) and Punicalagin (PUNI). They downregulate cyclin B1 and cyclin A to stall the cell cycle in the S phase in colon cancer cells, yet normal colon cells appear to have a "tolerance" to these compounds, suggesting a natural therapeutic window.
  • Metastasis "Lockdown": Tannins don't just kill cells; they prevent them from moving. Extracts from Terminalia catappa (TCE) were found to reduce the activity of proteolytic enzymes like MMP-2 and MMP-9. By preventing the degradation of the extracellular matrix, tannins effectively "lock" tumor cells in place, preventing migration.
  • The Gut-Immune Axis: The paper highlights a fascinating indirect mechanism: tannins act as prebiotics. They increase the output of Short-Chain Fatty Acids (SCFAs) by 70–820 times compared to conventional foods. These SCFAs then fine-tune the immune response, potentially enhancing the efficacy of Immune Checkpoint Inhibitors (ICIs).
  • The ROS Paradox: While tannins are famous as antioxidants that scavenge Reactive Oxygen Species (ROS) to prevent DNA damage, they can also increase ROS concentrations within the specific microenvironment of a tumor to trigger mitochondrial apoptosis—a dual-role functionality depending on the cellular context.

Key Results

  • Cell Cycle Control: Corilagin was shown to significantly block the G0/G1 phase in esophageal cancer cells by decreasing CDK4/6 and cyclin D1 expression while increasing the p21 inhibitor.
  • Apoptosis Induction: Compounds like TMEA (trimethylellagic acid) decrease the Bcl-2/Bax ratio, a critical switch that triggers the release of cytochrome c from the mitochondria, leading to programmed cell death.
  • Angiogenesis Inhibition: PGG (pentagalloyl glucose) was found to inhibit the binding of Vascular Endothelial Growth Factor (VEGF) to its receptors, essentially "starving" the tumor of the new blood vessels it needs to grow and spread.

Limitations and Future Work

The authors acknowledge several hurdles that prevent tannins from becoming mainstream clinical treatments:

  1. Low Bioavailability: Tannins are often unstable; they can be degraded by enzymes, temperature, or pH changes in the digestive tract before reaching the target organ.
  2. Separation Costs: Isolating pure tannin monomers from complex plant matrices is technically difficult and expensive.
  3. Synergy vs. Purity: While many studies focus on isolated monomers, TCM often relies on the synergistic effects of multiple compounds. Future research needs to explore these "synergy points" more deeply.

Proposed Solution: The authors suggest that nano-delivery systems could be the key to protecting tannin structures and ensuring they reach tumor sites at therapeutic concentrations.

Summary updated

Abstract

By reviewing the literature on the efficacy of tannins in traditional Chinese medicine in the last decade or so, we have classified the anti-tumor mechanism of tannins in conjunction with the latest mechanism exploration in the field of oncology. Tannins, a class of multi-phenolic compounds widely present in the diet, have been studied by scholars worldwide in recent years because of their relatively outstanding pharmacological activities. The mechanisms of anti-tumor action of tannins can be summarized as follows: the arrest of the cell cycle, arrest of tumor migration, enhancement of immune competence, induction of apoptosis, and antioxidant effects.
BibTeX
@article{ding2023research,
  author = {Hui Ding and Yuxin Wang and Gen Li and Yingling Dong and Xinyu Dai and Chenglong Kang and Kai Li and Haixing Han and Xuling Peng and Xi Chen},
  title = {{Research Progress on Anti-Tumor Mechanism of Tannins in Traditional Chinese Medicine}},
  journal = {Journal of Biomedical Research \& Environmental Sciences},
  year = {2023},
  doi = {10.37871/jbres1736},
}
Figure